rheumatic diseases

Summary

Introduction. Antinuclear antibodies are used in diagnostics of rheumatic diseases. By indirect immunofluorescence dense fine speckled fluorescence pattern can be detected, which is associated with anti- DFS70 antibodies. It is thought that anti- DFS70 antibodies can be a useful biomarker to rule out rheumatic diseases. The aim of this study was to investigate the prevalence of anti-DFS70 antibodies and their association with other antinuclear antibodies in patients with rheumatic diseases.

Summary

Summary

Background. Formation of antibodies (Ab) to TNFa blockers (adalimu-mab (ADA), etanercept (ETA) and infliximab (INF)) inversely correlates with functional drug levels and clinical effect. Comparison of drug levels and anti-drug Ab monitoring is hampered by lack of standardization.

Aim. To determine the correlation and agreement between two different assays for measurement of TNFa blockers and anti-drug Ab levels.